Lactoferrin (LF), a cationic 80-kDa protein present in polymorphonuclear leukocytes and in mucosal secretions, is known to have antibacterial effects on gram-negative bacteria, with a concomitant release of lipopolysaccharides (LPS, endotoxin). In addition, LF is known to decrease LPS-induced cytokine release by monocytes Lactoferrin (LF) is a cationic (calculated pl = 8.5) 80-kDa protein present at high concentrations in the specific granules of polymorphonuclear leukocytes and in mucosal secretions (22) . LF has bacteriostatic and bactericidal effects and is thought to contribute to host defense, both systemically and at mucosal surfaces. LF exhibits antibacterial effects on gramnegative bacteria by means of two mechanisms. Firstly, it is an iron-binding protein, which limits the amount of free iron; iron is an essential growth factor for microorganisms (18). Secondly, LF is capable of destabilizing the outer membrane of gram-negative bacteria, which results in liberation of lipopolysaccharides (LPS) (6). One possible mechanism of action is the binding by LF of divalent cations (Ca2+ and Mg2+) that neutralize and stabilize the negative charges of LPS (7); this mechanism of action is similar to the destabilizing effect of the metal chelator EDTA on the gram-negative outer membrane. An alternative mechanism for the liberation of LPS is the direct interaction of the cationic LF with the anionic LPS, followed by its withdrawal from the outer membrane (5). Possibly, the negative charges in LPS involved in this interaction are the carboxyl groups on 3-deoxy-D-manno-octulosonate (KDO) present in the inner core and the phosphate residue(s) present in the lipid A part of LPS. This mechanism is similar to that of polymyxin B (PMB), a cationic outer membranedestabilizing peptide, which binds directly to the lipid A part of LPS (14).
Lactoferrin (LF) is a cationic (calculated pl = 8.5) 80-kDa protein present at high concentrations in the specific granules of polymorphonuclear leukocytes and in mucosal secretions (22) . LF has bacteriostatic and bactericidal effects and is thought to contribute to host defense, both systemically and at mucosal surfaces. LF exhibits antibacterial effects on gramnegative bacteria by means of two mechanisms. Firstly, it is an iron-binding protein, which limits the amount of free iron; iron is an essential growth factor for microorganisms (18) . Secondly, LF is capable of destabilizing the outer membrane of gram-negative bacteria, which results in liberation of lipopolysaccharides (LPS) (6) . One possible mechanism of action is the binding by LF of divalent cations (Ca2+ and Mg2+) that neutralize and stabilize the negative charges of LPS (7); this mechanism of action is similar to the destabilizing effect of the metal chelator EDTA on the gram-negative outer membrane. An alternative mechanism for the liberation of LPS is the direct interaction of the cationic LF with the anionic LPS, followed by its withdrawal from the outer membrane (5) . Possibly, the negative charges in LPS involved in this interaction are the carboxyl groups on 3-deoxy-D-manno-octulosonate (KDO) present in the inner core and the phosphate residue(s) present in the lipid A part of LPS. This mechanism is similar to that of polymyxin B (PMB), a cationic outer membranedestabilizing peptide, which binds directly to the lipid A part of LPS (14) .
The goal of this study was to investigate systematically, by in vitro-binding studies, the direct interaction of LF with lipid A and LPS of relevant serotypes of gram-negative bacteria that are frequently involved in sepsis and shock, i.e., Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa (4, 9, 12) ; the interaction with LPS of mucosal pathogens (such as Neisseria spp. and Haemophilus influenzae) was also studied.
LF was purified from fresh human milk by cation-exchange chromatography on Mono S (HR 5/5; Pharmacia) in 20 mM sodium phosphate buffer (pH 7.5). LF eluted as a single peak at 0.68 M NaCl when a linear 0 to 1 M gradient was used. The sensitivity of the detector was set to 0.01. Gel filtration of purified LF on Superose 12 (HR 10/30; Pharmacia) again showed a single symmetrical peak in absorption and in a nanogram-sensitive radioimmunoassay specific for LF. This excludes the presence of LF polymers. The results of Nterminal protein sequencing showed the presence of a single N terminus of intact LF. Measurement ofA280 and A265 revealed LF to be saturated with iron at about 3.5%. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed pure LF migrating as a closely spaced doublet of protein bands at 80 kDa. LPS contamination of LF was less than 2 U (200 pg) of endotoxin per mg of LF, as estimated by the Limulus assay (Kinetic-QCL; BioWhittaker). LF (20 mg/ml in 0.9% NaCl) was stored in portions at -80°C. Portions were thawed, brought to 4°C, and used within 6 days. Affinity-purified polyclonal anti-LF antibodies were prepared from rabbit antihuman LF (Sigma) as described previously (16) . Antibodies were kept at -80°C and for daily use were stored at 4°C in the presence of 0.01% merthiolate.
Synthetic biphosphoryl E. coli lipid A (compound 506) was purchased from Daiichi Fine Chemicals (Tokyo, Japan). Natural biphosphoryl lipid A (lipid A-HAc) and monophosphoryl lipid A (lipid A-HCl) isolated from E. coli F515 (Re chemotype) LPS by hydrolysis with acetate buffer and hydrochloric acid, respectively, were gifts from H. Brade acrylamide, was prepared by P. Kosma. The copolymer, a 60-kDa polyvalent antigen, contains KDO-KDO disaccharide in an ox-2.4 linkage, i.e., the same as that occurring in the natural core (la) . PMB sulfate was obtained from by Pfizer (Brussels, Belgium).
The binding of LF to LPS was investigated by enzyme-linked immunosorbent assay (ELISA). LPS or lipid A was coated for 16 h at room temperature at 1 ,ug/ml in 100 RI of pyrogen-free phosphate-buffered saline (PBS; pH 7.2) onto the surface of polystyrene 96-well plates (Immulon, medium binding capacity; Greiner, Alphen aan den Rijn, The Netherlands). The plates were washed thrice with PBS containing 0.01% Tween and 0.01% merthiolate (PBST). LF was diluted in twofold increments in concentrations ranging from 1 ,ug/ml to 1 ng/ml in pyrogen-free PBST (100 RI) and incubated for 16 h at room temperature. The plates were washed thrice, incubated for 3 h at 37°C in anti-LF (1 ,ug/ml in 100 ,u of PBST), washed thrice, incubated for 2 h at 37°C with horseradish-labelled goat antiserum to rabbit immunoglobulin G (heavy and light chains; Nordic, Tilburg, The Netherlands), and diluted 1:1,000 in PBST containing 0.5% goat serum. Then, plates were washed thrice, and color was allowed to develop for 30 min at room temperature in 100 RI of phosphate-citrate buffer (pH 5.5) containing 1 mg of orthophenylenediamine per ml and 0.015% hydrogen peroxide per ml. The reaction was stopped by the addition of 50 RI of 1:10-diluted concentrated sulfuric acid, and the plates were read at 492 nm.
Inhibition experiments. The ability of poly-oa-(KDO)2 and lipid A-HCl of E. coli to inhibit the binding of LF to LPS of P. aeruginosa IT-1 was investigated. A 100-pA portion of LF (500 ng/ml) in PBST was mixed with 100 pA of lipid A-HAc of E. coli or poly-a-(KDO)2, in concentrations ranging from 0.2 ng/ml to 20 ,ug/ml in 10-fold increments; the mixture was incubated for 1 h at 37°C. The mixture (100 pA) was then added to washed plates already coated with LPS, and the ELISA was finished as described above. LF (250 ng/ml) incubated with PBST served as a control representing 100% binding. The ability of PMB to inhibit the interaction between LF and LPS was investigated by two procedures. In the first procedure, PMB (100 pA), diluted in PBST in concentrations ranging from 0.1 ng/ml to 100 ,ug/ml in 10-fold increments, was added to washed plates already coated with LPS of P. aeruginosa IT-1 and incubated for 1 h at 37°C. The plates were washed, LF (250 ng/ml) was added, and the ELISA was finished as described above. In the second procedure, the plates were not washed after the incubation of PMB, LF (10 plA at a concentration of 2.5 ,ug/ml) was added to the LPS-coated PMB-containing wells, and the ELISA was done as described previously.
Negative controls in the direct binding studies included wells coated with PBS instead of LPS, and these wells were processed as described above. This control measured the nonspecific sticking of LF to plastic. As another control, LPS-coated wells were incubated with PBST substituted for LF, after which the ELISA was done as described above. Direct binding studies were done on two to six separate occasions. Inhibition studies were done in triplicate on two separate occasions. Representative results are presented either in the form of full titration curves or, alternatively, as titers (defined as the smallest amount of LF that still yielded an optical density [OD] of 0.2 above the sum of the results of the two negative controls).
Binding of LF to lipid A of various origins is shown in Fig.   1A . For negative controls, when LF was omitted ODs of 0.1 to 0.2 were obtained. When lipid A (or LPS, see below) was omitted, the ODs were 0.4 for 1,000 ng of LF per ml, 0.3 for 250 ng/ml, and 0.2 for 63 ng/ml (Fig. 1A) . We next investigated (Fig. 1B) and PMB are competing for the same binding site on LPS or to binding sites in close proximity; these findings suggest the possibility that LF may exhibit some of the same effects that PMB has on LPS bioactivity, e.g., inhibition of its ability to induce cytokines (see below). Finally, we investigated whether the binding of LF to lipid A was saturable. These studies were done at coating concentrations of 10 and 100 ng/ml. Results for 10 ng/ml are shown in Fig. 3 Our data demonstrate that LF binds to the lipid A part of LPS of clinically relevant bacterial species. Direct binding to lipid A has not been reported before. As far as we know, previous work on the in vitro binding of LF to LPS has been restricted to two LPSs of E. coli (5, 13) . It is possible that the direct binding of LF to LPS, followed by withdrawal of LPS from the outer membrane, accounts, in part, for its antibacterial effects, whether in vitro or in vivo, i.e., when bacteria are ingested within phagocytes during the process of oxygenindependent killing or when bacteria are on mucosal surfaces. The decreasing antibactericidal activity of LF on bacteria with increasing core lengths (15) would be in agreement with an involvement of LPS binding in this process.
Our findings may also explain a totally different line of data. LF has very recently been reported to decrease LPS-induced cytokine release by monocytes (3) . In addition, LF was capable of blocking LPS priming of human neutrophils for production of superoxide (2) . These effects may be due to direct binding of LF to LPS, which decreases its bioactivity, an effect that also occurs when LPS binds to bactericidal/permeability-increasing proteins (8) , another protein present in the granules of polymorphonuclear leukocytes. Interestingly, many of the antimicrobial proteins present in polymorphonuclear leukocyte granules bind to LPS (17) . Bactericidal/permeability-increasing protein is known to block LPS-induced cytokine secretion in vitro (8) and to cause protection against endotoxic death in vivo (8) . Likewise, the cationic, membrane-active oligopeptide PMB binds to the lipid A part of LPS (14) , blocks LPS-induced tumor necrosis factor secretion in vitro (23) , and protects in vivo (19) . Under the assumption that polymorphonuclear leukocyte-derived LF behaves in a manner similar to that derived from milk, it is possible that the in vivo protective effect of LF on the course of lethal gram-negative infection (24) is at least partially due to its anti-endotoxic effect. In agreement with this possibility is a recent report (11) showing that infusion of LF into mice prior to LPS challenge decreases the concentration of cytokines in the circulation.
In summary, LF binds to the lipid A part of LPS of clinically relevant bacteria, and this may result in bacterial growth reduction and/or killing, as well as in decreased endotoxicity of LPS occurring both in the bloodstream and at mucosal surfaces. Further studies of LPS as an anti-endotoxin agent are therefore warranted.
